Treatment
Annex 6. Statistical analysis plans
WHO treatment guidelines for drug-resistant TB treatment
WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis, 2018 update
Refer to Annex 10: Summaries of unpublished data and analysis plans used for the recommendations in the WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis, 2018 update.
https://iris.who.int/bitstream/handle/10665/311390/WHO-CDS-TB-2019.3-eng.pdf
Annex 5. GRADE evidence profiles and evidence-to-decision tables
5.1 Drug-susceptible TB
5.1.1 Guidelines update 2010 to 2022
Refer to WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment: web annexes. Web Annex 4
Annex 4. PICO questions
4.1. Drug-susceptible TB
Research questions in a Population, Intervention, Comparator, Outcomes (PICO) format are listed below as they related to the recommendations retained in this policy consolidation.
4.1.1. Guideline update 2010
Recommendation 1. PICO question
Should new pulmonary TB patients be treated with the 6-month or the 2-month rifampicin regimen?
Recommendation 2. PICO question
3.2 Drug-resistant tuberculosis treatment
WHO guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update
Funding for the meetings and reviews involved in the updating of the guidelines came entirely from the United States Agency for International Development (USAID). The experts on the Guideline Development Group (GDG) and the institutions where they work contributed time for the various discussions and other activities involved in the update process.
3.1 Drug-susceptible tuberculosis treatment
2009 Guideline Development Group:
All members of the group completed a Declaration for the Conflict of Interest; there were no conflicts declared.
2016 Guideline Development Group:
The following members declared no interests: Si Thu Aung; Frank Bonsu; Jeremiah Chakaya; Lucy Chesire; Daniela Cirillo; Poonam Dhavan; Kathy Fiekert; Andrei Mariandyshev; Nguyen Viet Nhung; Ejaz Qadeer; Abdul Hamid Salim; Holger Schünemann; Pedro Suarez; Justin Wong Yun Yaw.
2.2 Expert panels
Drug-susceptible TB treatment
Participants in the Guideline Development group meeting on Drug-susceptible TB in 2009
Guideline Development Group
Solange Cavalcante, TB Control Program Coordinator, Rio de Janeiro municipality, Rio de Janeiro, RJ, Brazil
Jeremiah Muhwa Chakaya (Chairperson), Technical Expert, National Leprosy and TB Programme, Kenya Medical Research Institute, Nairobi, Kenya
2.1 Methods
Since 2007, the guideline development process within the WHO has been overseen by the WHO Guidelines Review Committee (GRC), which follows internationally recognized standards such as the GRADE approach [Grading of Recommendations Assessment, Development, and Evaluation], to support a structured and transparent methodology for policy-making. The policy recommendations presented in the guideline document were developed following the standards and updated procedures as described in the WHO Handbook for Guideline Development.
Pagination
- Page 1
- Next page